The article, A Tiny Factory: Scaffolding a solution to macular telangiectasia with encapsulated cell therapy, was published by The Ophthalmologist and written by Thomas Aaberg, Jr., explores how ECT can improve MacTel patient outcomes, highlighting the general mechanism of action and the specific design choices made during development.

ABOUT THE AUTHOR: Thomas Aaberg, Jr., retinal surgeon at the Retina Specialists of Michigan, and the Chief Medical Officer of Neurotech Pharmaceuticals.